LifeSciVC
1,417 FOLLOWERS
I'm Bruce Booth. I'm an early-stage venture capitalist. Like my partners at Atlas Venture, I enjoy working with great scientists and entrepreneurs to start new biotech companies. Blog covers articles on all facets of early stage biotech.
LifeSciVC
4d ago
By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From The Trenches feature of LifeSciVC Given everything going on in our world right now, I’ve been thinking a lot about the state of biotech innovation…particularly as we wrestle
The post The Sweetest Thing appeared first on LifeSciVC ..read more
LifeSciVC
2w ago
By Ankit Mahadevia, serial biotech entrepreneur and former CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC I recently had an illuminating discussion with a seed-stage biotech Founder, who was reflecting after a hard and
The post Pitfalls Of The Scarcity Mindset appeared first on LifeSciVC ..read more
LifeSciVC
3w ago
By Cody Tranbarger, EIR at Atlas Venture, as part of the From The Trenches feature of LifeSciVC For decades, muscular dystrophy has stubbornly persisted among the most intractable categories of human disease. Despite recent progress with AAV Gene Therapy and
The post Dancing with the DGC: Structural Biology Meets Muscular Dystrophy appeared first on LifeSciVC ..read more
LifeSciVC
1M ago
By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC In the perpetual and never-ending race by the healthcare sector to unearth new approaches and therapeutics to address disease, one area in which
The post A New Wave of Therapeutic Innovation Through Targeting Transcription Factors appeared first on LifeSciVC ..read more
LifeSciVC
1M ago
By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC “It was the best of times, it was the worst of times…” Another JPM is behind us, and while much of the small
The post A Tale of Two Sentiments: JPM 2025 appeared first on LifeSciVC ..read more
LifeSciVC
3M ago
Today we announced the closing of Atlas Venture Fund XIV, a $450M investment vehicle focused exclusively on early stage biotech investing. With the closing of Fund XIV, we’re privileged to be able to continue backing innovative new biotech companies for
The post Atlas XIV And Reflections On The VC Math Problem appeared first on LifeSciVC ..read more
LifeSciVC
4M ago
“May you live in interesting times” – or so goes the phrase. In 1966, RFK Jr’s father famously used that quote to capture the turbulence of the times, and continued: “Like it or not, we live in interesting times. They
The post Atlas Venture 2024 Year In Review appeared first on LifeSciVC ..read more
LifeSciVC
4M ago
Today’s market likes products. Platforms aren’t in vogue anymore. Investors, especially in the public markets, only want late stage de-risked assets. Pharma only seems to be buying these kinds of asset. VCs need to focus on clinical stage companies. Or
The post Biotech Risk Cycles: Assets And Platforms appeared first on LifeSciVC ..read more
LifeSciVC
5M ago
By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC HotSpot’s trip to Barcelona for the recent European Society of Medical Oncology (ESMO) Annual Meeting was no ‘European Vacation,’ but it was certainly
The post ESMO Reflections: Glimmers of Hope with the Next Wave of I-O Therapies? appeared first on LifeSciVC ..read more
LifeSciVC
6M ago
By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC In an industry where boom and bust cycles occur regularly and 90 percent of drug candidates fail to reach the market, an outstanding
The post Reflections On My Experience As A Board Member appeared first on LifeSciVC ..read more